Are semaglutide tablets as good as the injections for weight loss?

You've heard injections get better results. Here's the honest picture.

The most common thing people tell us when they first look at the Wegovy tablet is some version of: "I saw the injection loses more weight, is the tablet worth bothering with?" It's a fair question, and the honest answer is: it depends what you're comparing and how much the delivery method matters to your day-to-day life.

The OASIS 4 trial, which formed the basis for the MHRA's June 2026 approval, found an average weight reduction of around 13.6% over 64 weeks, measured on an intention-to-treat basis, meaning it includes everyone who started the tablet regardless of how consistently they took it. Among those who followed the regimen fully, the average rose to about 17%. The STEP 1 trial for the 2.4mg injection reported roughly 15% average loss over 68 weeks in a similar population. These are not the same study, and small differences in who was enrolled matter, so you cannot read off a precise "the injection wins by X%" from these numbers alone.

What is fair to say is that the injection's average lands higher than the tablet's average, but the tablet's best-adherence figure overlaps with the injection's typical result. Whether that gap is meaningful for you personally (and whether a prescriber thinks the tablet is appropriate) depends on factors like your starting weight, any other health conditions, and how reliably you can follow the morning routine. The comparison between tablet and injection formats goes deeper than trial percentages alone.

What the tablet asks of you that the injection doesn't

The Wegovy tablet contains semaglutide combined with an absorption enhancer called SNAC. Without the right conditions, very little semaglutide crosses from the stomach into the bloodstream. That's why the timing rule is non-negotiable: take it first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120ml). Then wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medicines. Coffee counts, the kettle can wait.

Swallow it whole. That's important too; breaking or chewing the tablet disrupts the way the absorption enhancer works. The injection, by contrast, simply needs to go into the right site once a week and be kept refrigerated between doses. Neither routine is difficult once it becomes habit, but they are different habits, and the tablet's is arguably stricter.

One quick check that takes less than a minute: before you start the tablet, look at every other medicine you take in the morning. Anything that needs to be taken on an empty stomach, or that interacts with delayed food intake, should be flagged with your prescriber before day one, not after. This is exactly the kind of detail a prescriber reviews during a consultation. If you're weighing up the formats, this page on choosing between semaglutide tablets or injections sets out the practical differences clearly.

Storage is one area where the tablet genuinely wins. No fridge, no cold chain, no worrying about whether it stayed below 8°C in your suitcase. For frequent travellers or people who simply find managing a refrigerated pen inconvenient, that matters. Our Wegovy tablet overview covers storage and practical handling in more detail.

Which people tend to find the tablet a better fit

Needle aversion is real and common. A question prescribers hear regularly is some version of: "Is there any way to do this without injecting myself?" For those people, the Wegovy tablet is a meaningful development, not a compromise they're tolerating, but genuinely the form they prefer. Adherence tends to be better when you're not dreading the dose, and better adherence correlates with better outcomes in the trial data.

The licensed eligibility criteria for the tablet are slightly different from the injection's. The Wegovy tablet is approved for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition, a profile broadly similar to the injection, though the specific thresholds and any comorbidity requirements are confirmed at the point of clinical assessment rather than assumed from a BMI number. The question of which format is better really only resolves case by case.

The injection holds one advantage the tablet doesn't yet match: a higher licensed maintenance dose. The MHRA approved a 7.2mg weekly semaglutide injection pen in April 2026, and early data suggest average weight loss approaching 20.7% at that dose, narrowing the gap with tirzepatide results. The tablet's ceiling is 25mg oral, which is a different unit of measurement (oral bioavailability is much lower than injected) and not directly comparable in milligrams. If achieving the highest possible percentage weight loss is the primary goal, a prescriber may lean toward the injection, particularly at the newer higher dose. If you want to understand more about how the two forms of semaglutide actually differ, this page explains whether the tablet and the injection are really the same thing.

For a sense of how the tablet sits within the broader range of weight-loss treatment options, our treatment overview is a good starting point. Costs vary between providers and formats, our Wegovy tablet pricing page sets out what's included in a single transparent price, with no subscription and no hidden fees.

The part a prescriber decides, not a webpage

Reading trial data is useful context. It is not a substitute for clinical assessment. Both semaglutide formats carry the same side-effect profile, gastrointestinal symptoms (nausea, loose stools, indigestion) are the most common, tending to be more noticeable early on and after dose increases, and usually settling as your body adjusts. The NHS medicines information for semaglutide sets out what to watch for and when to seek help. There are also situations where either format may not be suitable (pregnancy, breastfeeding, certain gastrointestinal conditions, some other medicines) which a prescriber goes through systematically.

At nume, every consultation is read by a GPhC-registered Independent Prescriber. A real clinician (not software) reviews what you've submitted, considers whether the tablet or injection is the more appropriate route given your full picture, and confirms whether treatment is clinically suitable at all. There's no waiting list. If it's right for you, things move quickly from there.

If you'd like to explore whether the Wegovy tablet or injection suits your situation, you can check your eligibility and start a free consultation with our clinical team.